Neuphoria Therapeutics has filed its definitive proxy statement for the 2025 Annual Meeting of Stockholders, urging stockholders to vote “FOR” both of its nominees. The Board is conducting a strategic review of alternatives to maximize value for all stockholders, despite challenges from dissident stockholders. Neuphoria’s nominees bring decades of relevant investment banking experience, critical for overseeing the strategic review process. The Company is focused on advancing pipeline programs and seeking to maximize stockholder value through a transparent and orderly process. Neuphoria welcomes constructive engagement with all stockholders and encourages voting for continuity with experienced Board nominees.

Read more at GlobeNewswire: Neuphoria Therapeutics Inc. Sends Letter to Stockholders